BridgeBio Pharma (BBIO) Share-based Compensation (2018 - 2026)

BridgeBio Pharma's Share-based Compensation history runs 9 years deep, the most recent figure standing at $33.2 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 28.44% year-over-year to $33.2 million; the TTM figure through Mar 2026 stood at $140.5 million (up 34.32% YoY), while the FY2025 annual figure was $133.0 million, up 38.86% from the prior year.
• Share-based Compensation came in at $33.2 million for Q1 2026 at BridgeBio Pharma, down from $34.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $37.3 million in Q2 2025 to a low of $18.7 million in Q3 2022.
• A 5-year average of $28.2 million and a median of $27.2 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 30.42% in 2022 and jumped 82.25% in 2023, its largest moves.
• BridgeBio Pharma's Share-based Compensation stood at $20.3 million in 2022, then soared by 82.25% to $37.0 million in 2023, then slipped by 18.63% to $30.1 million in 2024, then grew by 14.98% to $34.6 million in 2025, then dropped by 4.03% to $33.2 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $33.2 million, $34.6 million, and $35.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison